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Abstract
Background: Little is known about physicians’ human papillomavirus (HPV) vaccine recommendations for
males while the Advisory Committee on Immunization Practices’ (ACIP) permissive guidelines for male
vaccination were in effect. The purpose of this study was to examine and explore factors associated with U.S.
physicians’ HPV vaccine recommendations to early (ages 11–12), middle (13–17), and late adolescent/young
adult (18–26) males.
Methods: Nationally representative samples of family physicians and pediatricians were selected in 2011
(n ¼ 1,219). Physicians reported the frequency with which they recommended HPV vaccine to male patients
["always" (>75% of the time) vs. other] for each age group. Statistically significant predictors of vaccine
recommendation were identified using multivariable logistic regression.
Results: The prevalence of physicians reporting they "always" recommended HPV vaccination for males
was 10.8% for ages 11 to 12, 12.9% for ages 13 to 17, and 13.2% for ages 18 to 26. Pediatrician specialty and self-
reported early adoption of new vaccineswere significantly associatedwith recommendation for all patient age
groups. In addition, physician race andpatient paymentmethodwere associatedwith physician recommenda-
tions to patients ages 11 to 12, and patient race was associated with recommendations to ages 13 to 17 and 18
to 26.
Conclusions: Less than 15% of physicians surveyed reported "always" recommendingHPV vaccine tomale
patients following national guidelines for permissive vaccination. Vaccine financing may have affected
physicians’ vaccine recommendations.
Impact: If these recommendation practices continue following the ACIP’s routine recommendation for
males in October 2011, then interventions designed to increase recommendations should target family
physicians and possibly use early adopters to encourage support of HPV vaccination guidelines. Cancer
Epidemiol Biomarkers Prev; 23(10); 2126–35. 2014 AACR.
Introduction
A growing body of evidence demonstrates the role of
humanpapillomavirus (HPV) in cancers that affectmales,
including anal, penile, and oropharyngeal cancer (1, 2).
Quadrivalent HPV vaccine trials have demonstrated high
levels of immunogenicity, reductions in genitalwarts, and
potential reductions in precancerous anogential lesions in
males (3, 4). Thus, vaccination has significant primary
prevention benefits for all males (5), but particularly for
those from racial/ethnic and sexualminority groups,who
are disproportionately affected by HPV-related diseases
(1, 6).
In the United States, the Advisory Committee on
Immunization Practices (ACIP), a national group of
medical and public health experts, develops recommen-
dations on how to use vaccines to control diseases (7).
The ACIP also collaborates with the American Academy
of Family Physicians and the American Academy of
Pediatrics to approve an immunization schedule for
persons ages 0 to 18 years (8). ACIP recommendations
can be "permissive," meaning that vaccine providers
may, but are not expected to, proactively offer vaccina-
tion, or may vaccinate upon request (9). In contrast, a
"routine" vaccine recommendation means that the vac-
cine should be proactively provided as the standard of
care.
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Private health insurance payers in the United States
reference theACIP’s recommendations to determine their
immunization coverage policy, and not all payers cover
immunizations with permissive recommendations (10).
Therefore, physician practices may choose to purchase
and stock only vaccines for which these costs are most
likely to be recouped and refer those who request these
vaccines to settings that are supported directly or indi-
rectly by the federal Vaccines for Children (VFC) pro-
gram. The VFC program provides VFC through age 18
years who are Medicaid eligible, uninsured, American
Indian or Alaska Native, or underinsured (11). Underin-
sured children, who have health insurance that does not
cover vaccines or covers selected vaccines, can receive
VFC-funded vaccines at a federally qualified health cen-
ter, rural health clinic, or under an approved deputization
agreement. The ACIP determines the vaccines that are
available through theVFC (12) and voted forHPVvaccine
coverage for males while permissive guidelines were in
effect (13, 14). In addition to vaccines provided through
theVFCprogram, state and local immunization programs
may elect to use state/local funds to purchase vaccines for
non-VFC eligible children (15).
In October 2009, the ACIP issued a permissive rec-
ommendation for vaccinating males ages 9 to 26 years
against HPV (16). Although early studies suggest that
pediatricians and family physicians support the concept
of male vaccination (17–22), these studies were primarily
conducted before the actual availability of the vaccine.
As such, little is known about actual recommendation
practices, particularly during the period between 2009
and 2011 when the ACIP’s permissive recommendation
was in effect. Examining physicians’ HPV vaccine
recommendations to males during a time of permissive
recommendations from the ACIP provides the oppor-
tunity to characterize "early adopter" providers (23),
establish a benchmark to which physician recommen-
dation after the ACIP’s 2011 routine recommendation
for males can be compared, and understand the poten-
tial impact on physician practices to inform the decision
for permissive recommendation for future vaccines.
As part of a larger study to examine trends in physi-
cians’ HPV vaccine recommendations to females (24, 25),
we surveyed physicians after the ACIP’s permissive
guidelines for male vaccination about their HPV vaccine
recommendations to male patients. On the basis of pre-
vious research that suggests differences in physicians’
HPV vaccine recommendations by patient age (24, 26),
recommendations in this study were assessed for males
ages 11 to 12 years (the target group forHPV vaccination),
ages 13 to 17 (a catch-up group that may still entail
parental involvement in vaccine decision-making), and
ages 18 to 26. This substudy was based on the Competing
DemandsModel (27), originally developed to understand
delivery of clinical preventive services in the primary care
setting and successfully applied by our team in prior
studies of physician recommendation for HPV vaccina-
tion to females (24, 25). The Competing Demands Model
proposes three domains of factors influencing physicians’
HPVvaccine recommendations. Physician factors include
personal characteristics, knowledge, beliefs, attitudes,
and experiences. Given the focus on adoption of a new
clinical practice (i.e., HPV vaccination), we drew upon
Diffusion of Innovations theory (23) to assess whether
physicianswho perceived themselves as early adopters of
new technologies were more likely to recommend HPV
vaccination. Patient factors include characteristics such as
payment method. Practice factors are the immediate set-
ting in which a physician delivers care (practice size,
geographic location, single vs. the multispeciality group).
Practice factors can also include issues outside the imme-
diate practice environment, such as state/policy factors
that may affect HPV vaccine recommendation (e.g.,
physician participation in the VFC program).
The primary aims of this study were to: (i) examine the
prevalence of physicians’ HPV vaccine recommendations
to early (ages 11–12), middle (13–17), and late adolescent/
young adult (18–26) males; and (ii) explore physician
factors associated with recommendation to each patient
age group after the ACIP issued permissive recommen-
dations for HPV vaccination.
Materials and Methods
Sample and recruitment
Study methods are described in greater detail else-
where (25). Briefly, a serial cross-sectional study was
conducted at 3 (2009) and 5 (2011) years post-HPVvaccine
licensure for females. Each year, nationally representative
samples of family physicians, pediatricians, and obstetri-
cians/gynecologists (OBGYN) were randomly selected
from theAmericanMedicalAssociation (AMA) Physician
Masterfile based on their proportional representation in
theU.S. primary care physicianworkforce. OBGYNswere
excluded from this study given that their practice focuses
on female patients. After obtaining the Institutional
Review Board approval, a recruitment approach based
on the Dillman (28) method was used and included six
varied contacts: prenotice postcard, survey packet mailed
via FedEx, reminder postcard, reminder survey packet
mailed via the U.S. Postal Service, another reminder
postcard, and a final survey packet mailed via the U.S.
Postal Service. Data used in this study were collected
between April 2011 and February 2012. Three surveys
were received after the ACIP guidelines for routine vac-
cination in October 2011, including one that the partici-
pant dated May 2011. Recommendation practices
reported on these surveys were variable, ranging from
"rarely" to "always," and, thus, these responses were
included in the current analyses.
The surveywasmailed to 746 family physicians and 473
pediatricians in 2011. Completed surveys were received
from 406 family physicians and 322 pediatricians. After
accounting for undeliverable surveys and ineligible par-
ticipants (e.g., non-patient care), the specialty-specific
response rate was 56.7% for family physicians and
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70.2% for pediatricians. To evaluate the national repre-
sentativeness of the sample,weused theAMA’sPhysician
Characteristics and Distribution in the United States (29)
to compare our study samples with the national data on
demographic and clinical practice characteristics. Our
samples were similar to the national population with
respect to region for both specialties and sex for family
physicians; however, a higher percentage of family phy-
sicians and pediatricians in our samples were in the older
age groups, and a higher percentage of pediatricians in
our sample were female.
Measures
Survey items anddevelopment aredescribed elsewhere
(24). The Competing Demands Model (27) and Diffusion
of Innovations (23) guided surveydevelopment. Predictor
and outcome variables included in the current analyses
are briefly described in the following paragraphs.
Predictor variables. Physicians were surveyed about
HPV information sources, HPV-related knowledge, vac-
cination barriers, vaccine practices, and vaccine recom-
mendation and administration practices. Vaccine prac-
tices included thenumber of strategies used to get patients
in for the first dose (e.g., sendpatient reminder about need
for preventive visit/checkup) and number of strategies
used to ensure three-dose series completion (e.g., send
reminder/recall letter or call patient). Physicians were
also asked whether they referred uninsured and under-
insured patients elsewhere for HPV vaccination. Given
that HPV vaccination formales was new at the time of the
study, two questions assessed whether physicians con-
sidered themselves early adopters of medical innovations
(23). Thesequestions askedphysicians about being among
the first to use a newly recommended vaccine compared
with clinical peers (five-point Likert-type scale ranging
from strongly disagree to strongly agree) and waiting to
adopt new medications, vaccines, or procedures until
hearing about them from several trusted colleagues (same
scale as previous item). Physician demographic, practice,
and patient data also were collected.
The survey contained 10 items tomeasure participants’
HPV-related knowledge, including items specific to U.S.
Food and Drug Administration approval of HPV vaccine
for males and noncervical cancers caused by HPV infec-
tion. Responses were summed to create a composite
knowledge score and dichotomized on the basis of a
median split: lower knowledge (0–7 correct responses)
and higher knowledge (8–10 correct responses). In addi-
tion, physicians were asked to report their agreement that
each of 14 items served as a barrier to immunizing their
patients against HPV; a mean barrier score was obtained
and a tertile split classified physicians as experiencing
low, medium, and high barriers.
Outcome variable. Physicians were asked to report
their HPV vaccine recommendation practices: "In the past
12 months, how often did you recommend the HPV
vaccine to your male patients?" Physicians provided sep-
arate responses for each patient age group. Response
options included a qualitative descriptor and quantitative
estimate: "never" (0%), "rarely" (1%–25%), "sometimes"
(26%–50%), "often" (51%–75%), "always" (>75%), or "do
not see patients in this age group."
Data analysis
Simple logistic regression models were used to deter-
mine the demographic and practice characteristics asso-
ciatedwith "always" recommendingHPVvaccine for each
patient age group. The final multivariable logistic regres-
sion model for each age group was selected using the
backward elimination approach (significance level of stay
¼ 0.05). The models were assessed for multicollinearity
among the predictor variables; variance inflation factors
suggest that multicollinearity was not problematic (most
values 1.5; all 3.5). Analyses were conducted using
SAS 9.3 (SAS Institute Inc.).
Results
As shown in Table 1, the largest proportions of physi-
cians were 50 years old (42.5%), White/Caucasian
(71.2%), and not Hispanic or Latino (91.6%). Most physi-
cians worked in a private practice setting (69.0%) and
reportedbeing aVFCprovider (58.2%).About 43%didnot
use any strategies to get patients in for the first dose of
HPV vaccine, whereas a higher percentage (57.1%)
reported using 2 strategies to ensure vaccine comple-
tion. More than a third of physicians (38.9%) reported
being among the first to use a newly recommended
vaccine compared with their clinical peers.
The percentage of physicians reporting they "always"
recommended HPV vaccination to males when permis-
sive guidelines were in effect was 10.8% for ages 11 to 12,
12.9% for ages 13 to 17, and 13.2% for ages 18 to 26.
Compared with family physicians, a higher percentage
of pediatricians reported consistent recommendation for
all age groups (Fig. 1). In bivariate analyses, the following
variables were associated with "always" recommending
HPV vaccine across all age groups: Pediatrician specialty;
VFC program participation; seeing primarily patients of a
race other than White; number of strategies used to get
patients in for the first dose and to ensure vaccine com-
pletion; being among the first to use a new vaccine; and
not waiting to adopt new medications, vaccines, or pro-
cedures (Table 2). Physicians of a race other than White,
who practiced in a multispecialty or "other" practice
environment, who did not refer underinsured patients
forHPVvaccination, andwithhigherHPV-relatedknowl-
edge also were more likely to consistently recommend
HPV vaccination to ages 11 to 12 and 13 to 17. Variables
associated with vaccine recommendation to only one age
group included northeast practice region (11–12), patient
payment method (11–12), perceived barriers to HPV vac-
cination (11–12), and not referring uninsured patients for
HPV vaccination (13–17).
In multivariable analysis, two factors were associated
with "always" recommending vaccination for all three
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Table 1. Demographic, practice, and patient
characteristics; knowledge; perceived barriers;
and vaccine practices in a representative
sample of U.S. physicians, 2011 (n ¼ 728)a
n (%)
Demographic characteristics
Age, y
30–39 137 (18.8)
40–49 260 (35.7)
50þ 309 (42.5)
Gender
Male 360 (49.5)
Female 361 (49.6)
Race
White/Caucasian 518 (71.2)
Other 197 (27.1)
Ethnicity
Hispanic or Latino 39 (5.4)
Not Hispanic or Latino 667 (91.6)
Practice characteristics
Provider specialty
Family Medicine 406 (55.8)
Pediatrics 322 (44.2)
Number of physicians
1 137 (18.8)
2–15 503 (69.1)
16þ 79 (10.9)
Number of specialties
Single 517 (71.0)
Multiple 178 (24.5)
Other 20 (2.8)
Type
Private practice 502 (69.0)
Other 216 (29.7)
Arrangement
Full/part-owner physician practice 337 (46.3)
Other 379 (52.1)
Number of patients/day
0–19 222 (30.5)
20–29 375 (51.5)
30þ 121 (16.6)
Location
Urban 193 (26.5)
Suburban 384 (52.8)
Rural 124 (17.0)
Other 8 (1.1)
Region
Northeast 151 (20.7)
Midwest 172 (23.6)
South 241 (33.1)
West 149 (20.5)
VFC provider
Yes 424 (58.2)
(Continued on the following column)(Continued in the following column)
Table 1. Demographic, practice, and patient
characteristics; knowledge; perceived barriers;
and vaccine practices in a representative sam-
ple of U.S. physicians, 2011 (n¼ 728)a (Cont'd )
n (%)
No 213 (29.3)
Do not know 76 (10.4)
Refer uninsured patients for vaccine
No or N/A 428 (58.8)
Yes, to federally qualiﬁed health center/
health department/other
300 (41.2)
Refer underinsured patients for vaccine
No or N/A 427 (58.7)
Yes, to federally qualiﬁed health center/
health department/other
301 (41.3)
Patient characteristics
Patient payment method
Private insurance/HMO
0%–50% of patients 343 (47.1)
51%–100% of patients 351 (48.2)
Patient race (majority)
Non-Hispanic White 502 (69.0)
Other 217 (29.8)
HPV knowledge
Lower (0–7 correct) 313 (43.0)
Higher (8–10 correct) 410 (56.3)
Perceived barriers related to HPV
vaccination
Low 218 (30.0)
Medium 236 (32.4)
High 263 (36.1)
Vaccine practices
Strategies for HPV vaccine initiation
0 314 (43.1)
1 168 (23.1)
2þ 212 (29.1)
Strategies to ensure HPV vaccine
completion
0 118 (16.2)
1 160 (22.0)
2þ 416 (57.1)
Early vs. late adopter
First to use a new vaccine
Agree 283 (38.9)
Neutral 263 (36.1)
Disagree 170 (23.4)
Wait to adopt
Agree 304 (41.8)
Neutral 195 (26.8)
Disagree 219 (30.1)
Abbreviations: HMO, health maintenance organization;
STIs, sexually transmitted infections.
aPercentages may not add up to 100% due to missing
data.
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patient age groups while adjusting for other factors:
pediatricians (vs. family physicians) and agreeing (vs.
disagreeing) that one was among the first to use a newly
recommended vaccine compared with clinical peers
(Table 3). Two factorswere independently associatedwith
"always" recommending vaccination for males ages 11 to
12: Physicians who reported a race other than White
(vs. White) and physicians who reported that 0% to
50% (vs. 51%–100%) of their patients used private insur-
ance as their primary paymentmethod. Finally, one factor
was significantly associated with "always" recommend-
ing vaccination for males ages 13 to 17 and 18 to 26:
Physicians who reported their patients were primarily of
a race other than White (vs. non-Hispanic White).
Discussion
Physicians’ recommendations seem to be one of the
most effective methods for increasing HPV vaccine
uptake (30–32), yet little research (26) has been conducted
to examine primary care physicians’ HPV vaccine recom-
mendations tomale patients. This study offers insight into
physician practices while HPV vaccine was available, but
not universally recommended, for males. Findings sug-
gest thatmost family physicians and pediatricians did not
consistently recommend HPV vaccination to males dur-
ing the ACIP’s permissive recommendation period.
Results from this study highlight key variables associated
with physicians’ HPV vaccine recommendation practices
while permissive guidelines were in effect.
Physician clinical specialty and early adoption of new
vaccines were associated with "always" recommending
HPV vaccine across all three patient age groups. Consis-
tent with prior research on HPV vaccination for females
(24, 25), pediatricians were more likely than family phy-
sicians to recommend HPV vaccination to males. If this
finding persists following the ACIP’s routine recommen-
dation for males, then this is concerning given that many
adolescent males may transition to the care of family
physicians as they move through adolescence; therefore,
family physicians could be critical for providing informa-
tion about and recommending vaccination (33).
In accordance with the Diffusion of Innovations theory
(23), physicians who self-identified as being among the
first to use a newly recommended vaccine (i.e., innova-
tors/early adopters) were more likely to "always" recom-
mend HPV vaccine when permissive guidelines were in
effect comparedwith later adopters. This findingparallels
previous research reporting that physicianswhowere late
adopters of newdrugs/vaccines or technologieswere less
likely to give HPV vaccine to all eligible patients (34) or
offer HPV vaccine (35). Innovators/early adopters have
more favorable attitudes toward change (23) andare likely
more knowledgeable about innovations. Innovators/ear-
ly adopters in our studymay have been routinely offering
HPV vaccine to males despite only permissive guidance
from the ACIP because they may have been more knowl-
edgeable about promising results from clinical trials of
HPV vaccine in males (16) and anticipated expanded
ACIP guidelines. Innovators/early adopters also may be
more tolerant of and have the resources to support risk
(36), such as financial resources to accept the risk of not
receiving reimbursement for vaccinating male patients.
Identifying and supporting innovators/early adopters
may facilitate diffusion of male HPV vaccination, given
these physicians are watched by colleagues as they test
evidence-based changes (e.g., feasibility of implementing
the new guidelines in clinical practice; ref. 36) and could
influence other physicians’ support (e.g., strength of rec-
ommendation) for HPV vaccination.
In addition to physician clinical specialty and early
adoption of new vaccines, patient payer status seems to
be associated with physicians’ HPV vaccine recommen-
dations to males. In this study, physicians whose patients
primarily used payment methods other than private
insurance (e.g., Medicaid, uninsured/self-pay) were
more likely to recommend HPV vaccine to males 11 to
12 years old. These patients likely were eligible for free
HPV vaccine, even during the permissive recommenda-
tion period, through the federal VFC program (13, 14).
Accordingly, more VFC eligible patients may have had
financial coverage for the vaccine comparedwith patients
with private insurance, and, thus, providers were more
likely to "always" recommend vaccination to these
patients. However, broader HPV vaccine coverage is
necessary to help ensure that physicians’ HPV vaccine
recommendations are aligned with ACIP guidelines and
not contingent upon patient payer status.
Along with the patient payment method, physician
and patient race/ethnicity were linked to physicians’
HPV vaccine recommendations. HPV-associated anal
cancer rates are higher for Black men compared with
White men (37) and sexually transmitted infection rates
tend to be higher in minority populations (38). Physi-
cians’ HPV vaccine recommendation practices may
have reflected their recognition of and desire to reduce
these disparities, particularly among physicians seeing
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Figure 1. The percentage of physicians who "always" (deﬁned as >75% of
the time) recommended HPV vaccine to males, by physician specialty and
patient age group. Note: In 2011, physicians seeing 11- to 12-year-old,
n ¼ 648; 13- to 17-year-old, n ¼ 658; and 18- to 26-year-old, n ¼ 597.
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Table 2. Physician demographic, practice, and patient characteristics; knowledge; perceived barriers; and
vaccine practices associated with HPV vaccine recommendation ("always" vs. other) by the patient age
group, 2011
Ages 11–12 (n ¼ 648)a Ages 13–17 (n ¼ 658)a Ages 18–26 (n ¼ 597)a
n OR (95% CI) n OR (95% CI) n OR (95% CI)
Demographic characteristics
Provider specialty
Family medicine 340 Reference 350 Reference 372 Reference
Pediatrics 308 4.3 (2.41–7.70)b 308 4.8 (2.78–8.13)b 225 5.0 (2.99–8.45)b
Age, y
50þ 269 Reference 274 Reference 257 Reference
40–49 237 0.6 (0.36–1.14) 240 0.8 (0.45–1.29) 214 0.8 (0.47–1.36)
30–39 125 0.9 (0.45–1.69) 126 0.9 (0.51–1.74) 112 0.8 (0.43–1.59)
Gender
Male 319 Reference 324 Reference 314 Reference
Female 325 1.3 (0.77–2.09) 330 1.5 (0.93–2.34) 279 1.4 (0.88–2.26)
Race
White/Caucasian 463 Reference 469 Reference 440 Reference
Other 176 2.0 (1.19–3.36)b 180 1.9 (1.17–3.03)b 150 1.3 (0.75–2.15)
Ethnicity
Not Hispanic or Latino 598 Reference 606 Reference 552 Reference
Hispanic or Latino 32 1.2 (0.40–3.45) 34 0.9 (0.30–2.55) 27 0.8 (0.23–2.71)
Practice characteristics
Number of physicians
2–15 461 Reference 466 Reference 417 Reference
1 115 1.1 (0.59–2.15) 118 0.8 (0.43–1.52) 112 0.7 (0.34–1.31)
16þ 65 1.4 (0.66–3.05) 67 1.0 (0.48–2.14) 62 1.0 (0.48–2.20)
Number of specialties
Single 470 Reference 476 Reference 437 Reference
Multiple 155 1.9 (1.08–3.24)b 159 1.7 (1.03–2.83)b 140 1.0 (0.56–1.74)
Other 17 5.9 (2.06–16.70)b 17 4.5 (1.61–12.81)b 13 3.0 (0.88–9.94)
Type
Other 175 Reference 178 Reference 162 Reference
Private practice 466 0.7 (0.40–1.14) 473 0.8 (0.47–1.26) 428 1.0 (0.58–1.66)
Arrangement
Other 330 Reference 337 Reference 304 Reference
Full/part-owner physician practice 309 1.0 (0.63–1.72) 312 1.1 (0.69–1.73) 286 1.3 (0.82–2.12)
Number of patients/day
30þ 114 Reference 115 Reference 103 Reference
20–29 351 0.7 (0.36–1.31) 357 0.8 (0.42–1.41) 315 0.9 (0.49–1.75)
0–19 178 0.9 (0.44–1.79) 181 0.9 (0.45–1.72) 175 0.8 (0.37–1.55)
Location
Suburban 347 Reference 353 Reference 324 Reference
Urban 164 1.6 (0.88–2.82) 167 1.4 (0.81–2.36) 149 1.2 (0.70–2.16)
Rural 115 1.6 (0.87–3.14) 116 1.4 (0.79–2.62) 104 1.2 (0.63–2.27)
Other 8 1.5 (0.17–12.22) 8 1.1 (0.13–9.32) 6 0.0 (0.00-¥)
Region
West 131 Reference 133 Reference 118 Reference
Northeast 136 0.4 (0.16–0.94)b 141 0.7 (0.32–1.38) 132 0.8 (0.37–1.58)
Midwest 159 0.8 (0.37–1.53) 159 0.9 (0.44–1.70) 149 1.0 (0.49–1.89)
South 210 0.9 (0.49–1.76) 213 1.1 (0.57–1.96) 186 0.8 (0.40–1.53)
(Continued on the following page)
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Table 2. Physician demographic, practice, and patient characteristics; knowledge; perceived barriers; and
vaccine practices associated with HPV vaccine recommendation ("always" vs. other) by the patient age
group, 2011 (Cont'd )
Ages 11–12 (n ¼ 648)a Ages 13–17 (n ¼ 658)a Ages 18–26 (n ¼ 597)a
n OR (95% CI) n OR (95% CI) n OR (95% CI)
VFC provider
No 162 Reference 167 Reference 170 Reference
Yes 416 2.1 (1.07–4.11)b 417 2.1 (1.14–3.84)b 350 2.4 (1.28–4.34)b
Do not know 60 0.7 (0.20–2.69) 64 0.5 (0.15–1.94) 67 0.7 (0.22–2.23)
Refer uninsured patients for vaccine
No or N/A 383 Reference 388 Reference 336 Reference
Yes, to federally qualiﬁed health center/health
department/other
265 0.6 (0.34–1.00) 270 0.5 (0.32–0.86)b 261 0.8 (0.47–1.24)
Refer underinsured patients for vaccine
No or N/A 381 Reference 386 Reference 336 Reference
Yes, to federally qualiﬁed health center/health
department/other
267 0.6 (0.34–0.99)b 272 0.5 (0.29–0.80)b 261 0.9 (0.57–1.47)
Patient characteristics
Patient payment method
Private insurance
51%–100% of patients 317 Reference 326 Reference 300 Reference
0%–50% of patients 309 1.8 (1.06–3.02)b 309 1.6 (0.96–2.50) 278 1.2 (0.76–2.00)
Patient race (majority)
Non-Hispanic White 454 Reference 458 Reference 429 Reference
Other 187 2.6 (1.56–4.27)b 193 2.3 (1.42–3.61)b 161 1.9 (1.16–3.10)b
HPV knowledge
Higher (8–10 correct) 381 Reference 384 Reference 350 Reference
Lower (0–7 correct) 264 0.6 (0.33–0.98)b 271 0.6 (0.37–0.99)b 244 0.6 (0.37–1.02)
Perceived barriers related to HPV vaccination
Overall
High 225 Reference 231 Reference 211 Reference
Medium 211 2.0 (1.05–3.81)b 215 1.7 (0.97–3.14) 203 1.5 (0.83–2.74)
Low 205 1.8 (0.94–3.50) 206 1.7 (0.94–3.08) 179 1.7 (0.92–3.07)
Vaccine practices
Strategies for HPV vaccine initiation
2þ 198 Reference 204 Reference 167 Reference
1 163 0.8 (0.43–1.49) 163 0.8 (0.43–1.36) 145 0.8 (0.43–1.38)
0 280 0.5 (0.30–0.98)b 284 0.5 (0.27–0.81)b 279 0.4 (0.21–0.65)b
Strategies to ensure HPV vaccine completion
2þ 393 Reference 400 Reference 348 Reference
1 152 1.0 (0.58–1.81) 153 1.0 (0.57–1.65) 142 1.0 (0.58–1.75)
0 96 0.2 (0.07–0.76)b 98 0.2 (0.09–0.69)b 101 0.4 (0.19–0.99)b
Early vs. late adopter
First to use a new vaccine
Disagree 145 Reference 148 Reference 146 Reference
Neutral 231 2.3 (0.73–7.05) 236 2.6 (0.97–7.22) 211 2.7 (1.07–6.88)b
Agree 267 8.5 (3.02–24.09)b 269 8.0 (3.15–20.51)b 235 6.3 (2.63–15.13)b
Wait to adopt
Agree 268 Reference 272 Reference 253 Reference
Neutral 175 0.7 (0.34–1.51) 178 0.9 (0.47–1.66) 156 1.0 (0.50–1.84)
Disagree 201 2.3 (1.33–4.07)b 204 1.9 (1.14–3.23)b 184 2.0 (1.14–3.38)b
NOTE: Rows containing statistically signiﬁcant variables are shaded for ease of viewing patterns across age groups.
Abbreviation: CI, conﬁdence interval.
aNumber of physicians who see male patients in the age group.
bStatistically signiﬁcant variable included in the multivariable model.
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a patient population that is not non-Hispanic White.
More research is needed to understand the role of race/
ethnicity in physicians’ HPV vaccine recommendations.
Given that physicians’ perceived barriers to immuniz-
ingpatientswere statistically significantly associatedwith
HPV vaccine recommendations for females (24, 25), an
interesting findingwas the lack of a significant association
between perceived barriers and HPV vaccine recommen-
dations for male patients. One possible explanation for
this result is the absence ofmale-specific barrier items and
the timing of survey. The assessment of physicians’ bar-
riers related to immunizing patients against HPV was
neutral with regard to patient sex and, because the ACIP
guidelines for males were permissive at the time of the
survey, physicians may have responded to the barrier
items with their female patients in mind. More recent
assessments of barriers to HPV vaccination suggest there
are male-specific barriers (39), such as lack of office visits
by adolescent male patients (26) and physicians’ belief
that vaccinating males is not worth the cost or effort (40).
Future assessments of physicians’ barriers to immunizing
patients against HPV should include these barriers.
This study has notable strengths, including the use of
nationally representative samples of physicians most
likely to be involved in male HPV vaccination and an
overall response rate exceeding 60%.Despite its strengths,
there are several limitations. First, the datamay be subject
to recall bias; however, self-reported measures are neces-
sary to assess physicians’ recommendation practices
given that recommendation may be inconsistently docu-
mented in medical records and cannot be assessed using
claims data. Similarly, physicians may have reported
socially desirable responses about practice behaviors,
although we attempted to minimize socially desirable
responses through an anonymous survey. Finally,
although our response rate exceeds that of other studies
of U.S. physicians pertaining to HPV vaccination (22, 41,
42), the responders to our survey may have had stronger
opinions aboutHPVvaccination ormore time to devote to
taking the survey than nonresponders. This issue may be
particularly relevant for family physicians, whose
response rates were lower than pediatricians.
Conclusions and Future Directions
This article provides a unique glimpse into physicians’
HPV vaccine recommendations early in the dissemination
of the vaccine for male patients. Overall rates of recom-
mendation were low and possibly influenced by the per-
missivenature of theACIP recommendation.However, the
study results largelymirror previous studies of recommen-
dations to females (24, 25) demonstrating the strong asso-
ciation between physician recommendation and specialty.
In addition, recommendation tomaleswas associatedwith
self-identification as an innovator/early adopter of new
vaccines. An important next step is to examine whether
physicians’ recommendation rates have improved now
that the vaccine is fully recommended by the ACIP, and,
thus, is more likely to be covered by private insurance. If
these same factors continue to be influential in predicting
recommendation practices, then public health interven-
tions designed to increase HPV vaccine recommendations
Table 3. Multivariable logistic regression analysis of factors associatedwithHPV vaccine recommendation
("always" vs. other)a by the patient age group, 2011
Patient age group adjusted OR (95% CI)
Predictor 11–12 (n ¼ 581) 13–17 (n ¼ 619) 18–26 (n ¼ 571)
Specialty
Family physician 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
Pediatrician 3.5 (1.82–6.74) 3.5 (1.95–6.23) 3.8 (2.23–6.50)
First to use a new vaccine
Disagree 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
Neutral 2.0 (0.55–7.49) 2.3 (0.74–6.92) 2.1 (0.81–5.38)
Agree 6.9 (2.05–23.06) 6.4 (2.21–18.24) 4.2 (1.72–10.37)
Physician race — —
White/Caucasian 1.0 (Reference)
Other 1.9 (1.06–3.46)
Patient payment method, private insurance — —
51%–100% of patients 1.0 (Reference)
0%–50% of patients 2.1 (1.18–3.81)
Patient race (majority) —
Non-Hispanic White 1.0 (Reference) 1.0 (Reference)
Other 2.0 (1.17–3.28) 1.8 (1.06–3.04)
Abbreviation: CI, conﬁdence interval.
aVariables were selected through backward selection at the level of stay a ¼ 0.05.
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for males should focus on increasing recommendations by
family physicians, who likely assume care of adolescent
males as they transition frompediatric settings. In addition,
identifyingandsupporting innovators/earlyadoptersmay
help diffuse HPV vaccination guidelines and encourage
later adopters to support guidelines.
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